Top

Intensive Care Medicine

Published in:

01-01-2015 | Correspondence

What is “severe burnout” and can its prevalence be assessed?

Author: Renzo Bianchi

Published in: Intensive Care Medicine | Issue 1/2015

Excerpt

Dear Editor, …

Burghi G, Lambert J, Chaize M et al (2014) Prevalence, risk factors and consequences of severe burnout syndrome in ICU. Intensive Care Med 40:1785–1786. doi:10.1007/s00134-014-3454-x PubMedCrossRef

Weber A, Jaekel-Reinhard A (2000) Burnout syndrome: a disease of modern societies? Occup Med 50:512–517CrossRef

Maslach C, Jackson SE, Leiter MP (1996) Maslach burnout inventory manual, 3rd edn. Consulting Psychologists, Palo Alto

Giannini A, Miccinesi G, Prandi E et al (2013) Partial liberalization of visiting policies and ICU staff: a before-and-after study. Intensive Care Med 39:2180–2187PubMedCrossRef

Bianchi R, Schonfeld IS, Laurent E (2014) Is burnout a depressive disorder? A reexamination with special focus on atypical depression. Int J Stress Manag. doi:10.1037/a0037906

Title: What is “severe burnout” and can its prevalence be assessed?
Author: Renzo Bianchi
Publication date: 01-01-2015
Publisher: Springer Berlin Heidelberg
Published in: Intensive Care Medicine / Issue 1/2015
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI: https://doi.org/10.1007/s00134-014-3534-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

What is “severe burnout” and can its prevalence be assessed?

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2015

Failure of renal biomarkers to predict worsening renal function in high-risk patients presenting with oliguria

The association between hyperoxia and patient outcomes after cardiac arrest: analysis of a high-resolution database

Unsolved questions in solid tumor patients and intensive care

Pulse oximetry vs. PaO2 metrics in mechanically ventilated children: Berlin definition of ARDS and mortality risk

Mortality is the only relevant outcome in ARDS: no

Type III procollagen is a reliable marker of ARDS-associated lung fibroproliferation